Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Identifieur interne : 001990 ( Main/Exploration ); précédent : 001989; suivant : 001991Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Auteurs : I. J. Diel [Allemagne] ; J.-J. Body [Belgique] ; M. R. Lichinitser [Russie] ; E. D. Kreuser [Allemagne] ; W. Dornoff [Allemagne] ; V. A. Gorbunova [Russie] ; M. Budde [Suisse] ; B. Bergström [États-Unis]Source :
- European journal of cancer : (1990) [ 0959-8049 ] ; 2004.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Pharmacologie.
English descriptors
- KwdEn :
Abstract
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life. It was the aim of the present study to assess changes in quality of life and bone pain due to intravenous (i.v.) ibandronate, a potent third-generation bisphosphonate. In a phase III randomised, double-blind, placebo-controlled trial in patients with bone metastases due to breast cancer, 466 women were randomised to receive placebo, 2 mg ibandronate or 6 mg ibandronate for up to 96 weeks. Treatment was administered i.v. at 3- or 4-weekly intervals. Clinical endpoints included the incidence of adverse events, quality of life (assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Scale - Core 30 questionnaire (QLQ-C30)), and bone pain (assessed on a 5-point scale from 0 = none to 4 = intolerable). Ibandronate was generally well tolerated. Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups, but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28 ± 1.11, P < 0.001). A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status. Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05). Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group. I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.
Affiliations:
- Allemagne, Belgique, Russie, Suisse, États-Unis
- Bade-Wurtemberg, District de Karlsruhe, District fédéral central, New Jersey, Région de Bruxelles-Capitale
- Bruxelles, Mannheim, Moscou
- Université libre de Bruxelles
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000B35
- to stream PascalFrancis, to step Curation: 000368
- to stream PascalFrancis, to step Checkpoint: 000925
- to stream Main, to step Merge: 001B92
- to stream Main, to step Curation: 001990
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer</title><author><name sortKey="Diel, I J" sort="Diel, I J" uniqKey="Diel I" first="I. J." last="Diel">I. J. Diel</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CGG-Klinik GmhH, Quadrat P7, 16-18</s1><s2>Mannheim 68181</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Body, J J" sort="Body, J J" uniqKey="Body J" first="J.-J." last="Body">J.-J. Body</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Université Libre de Bruxelles, Institut Jules Bordet</s1><s2>Bruxelles</s2><s3>BEL</s3><sZ>2 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Lichinitser, M R" sort="Lichinitser, M R" uniqKey="Lichinitser M" first="M. R." last="Lichinitser">M. R. Lichinitser</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Clinical Chemotherapy, Cancer Research Center</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Kreuser, E D" sort="Kreuser, E D" uniqKey="Kreuser E" first="E. D." last="Kreuser">E. D. Kreuser</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Krankenhaus der Barmherzigen Brueder, Onkologische Ambulanz</s1><s2>Regensburg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Regensburg</wicri:noRegion><wicri:noRegion>Onkologische Ambulanz</wicri:noRegion><wicri:noRegion>Regensburg</wicri:noRegion></affiliation></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mutterhaus der Borromaeerinnen</s1><s2>Trier</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Mutterhaus der Borromaeerinnen</wicri:noRegion><wicri:noRegion>Mutterhaus der Borromaeerinnen</wicri:noRegion></affiliation></author><author><name sortKey="Gorbunova, V A" sort="Gorbunova, V A" uniqKey="Gorbunova V" first="V. A." last="Gorbunova">V. A. Gorbunova</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Chemotherapy, Cancer Research Center</s1><s2>Moscow</s2><s3>RUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Budde, M" sort="Budde, M" uniqKey="Budde M" first="M." last="Budde">M. Budde</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>F. Hoffmann-La Roche Ltd</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>F. Hoffmann-La Roche Ltd</wicri:noRegion></affiliation></author><author><name sortKey="Bergstrom, B" sort="Bergstrom, B" uniqKey="Bergstrom B" first="B." last="Bergström">B. Bergström</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Hoffmann-La Roche Inc.</s1><s2>Nutley, NJ</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0480323</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0480323 INIST</idno><idno type="RBID">Pascal:04-0480323</idno><idno type="wicri:Area/PascalFrancis/Corpus">000B35</idno><idno type="wicri:Area/PascalFrancis/Curation">000368</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000925</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000925</idno><idno type="wicri:doubleKey">0959-8049:2004:Diel I:improved:quality:of</idno><idno type="wicri:Area/Main/Merge">001B92</idno><idno type="wicri:Area/Main/Curation">001990</idno><idno type="wicri:Area/Main/Exploration">001990</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer</title><author><name sortKey="Diel, I J" sort="Diel, I J" uniqKey="Diel I" first="I. J." last="Diel">I. J. Diel</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CGG-Klinik GmhH, Quadrat P7, 16-18</s1><s2>Mannheim 68181</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Body, J J" sort="Body, J J" uniqKey="Body J" first="J.-J." last="Body">J.-J. Body</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Université Libre de Bruxelles, Institut Jules Bordet</s1><s2>Bruxelles</s2><s3>BEL</s3><sZ>2 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Lichinitser, M R" sort="Lichinitser, M R" uniqKey="Lichinitser M" first="M. R." last="Lichinitser">M. R. Lichinitser</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Clinical Chemotherapy, Cancer Research Center</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Kreuser, E D" sort="Kreuser, E D" uniqKey="Kreuser E" first="E. D." last="Kreuser">E. D. Kreuser</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Krankenhaus der Barmherzigen Brueder, Onkologische Ambulanz</s1><s2>Regensburg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Regensburg</wicri:noRegion><wicri:noRegion>Onkologische Ambulanz</wicri:noRegion><wicri:noRegion>Regensburg</wicri:noRegion></affiliation></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mutterhaus der Borromaeerinnen</s1><s2>Trier</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Mutterhaus der Borromaeerinnen</wicri:noRegion><wicri:noRegion>Mutterhaus der Borromaeerinnen</wicri:noRegion></affiliation></author><author><name sortKey="Gorbunova, V A" sort="Gorbunova, V A" uniqKey="Gorbunova V" first="V. A." last="Gorbunova">V. A. Gorbunova</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Chemotherapy, Cancer Research Center</s1><s2>Moscow</s2><s3>RUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Russie</country><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Budde, M" sort="Budde, M" uniqKey="Budde M" first="M." last="Budde">M. Budde</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>F. Hoffmann-La Roche Ltd</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>F. Hoffmann-La Roche Ltd</wicri:noRegion></affiliation></author><author><name sortKey="Bergstrom, B" sort="Bergstrom, B" uniqKey="Bergstrom B" first="B." last="Bergström">B. Bergström</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Hoffmann-La Roche Inc.</s1><s2>Nutley, NJ</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Bisphosphonates</term><term>Bone</term><term>Bone cancer</term><term>Bone disease</term><term>Breast cancer</term><term>Breast disease</term><term>Cancerology</term><term>Human</term><term>Ibandronic acid</term><term>Intravenous administration</term><term>Long term</term><term>Malignant tumor</term><term>Mammary gland</term><term>Metastasis</term><term>Pain</term><term>Pharmacology</term><term>Quality of life</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Métastase</term><term>Qualité vie</term><term>Long terme</term><term>Ostéopathie</term><term>Traitement</term><term>Bisphosphonates</term><term>Sein pathologie</term><term>Acide ibandronique</term><term>Homme</term><term>Tumeur maligne</term><term>Stade avancé</term><term>Os</term><term>Douleur</term><term>Glande mammaire</term><term>Voie intraveineuse</term><term>Cancérologie</term><term>Pharmacologie</term><term>Cancer de l'os</term><term>Cancer du sein</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Pharmacologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life. It was the aim of the present study to assess changes in quality of life and bone pain due to intravenous (i.v.) ibandronate, a potent third-generation bisphosphonate. In a phase III randomised, double-blind, placebo-controlled trial in patients with bone metastases due to breast cancer, 466 women were randomised to receive placebo, 2 mg ibandronate or 6 mg ibandronate for up to 96 weeks. Treatment was administered i.v. at 3- or 4-weekly intervals. Clinical endpoints included the incidence of adverse events, quality of life (assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Scale - Core 30 questionnaire (QLQ-C30)), and bone pain (assessed on a 5-point scale from 0 = none to 4 = intolerable). Ibandronate was generally well tolerated. Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups, but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28 ± 1.11, P < 0.001). A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status. Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05). Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group. I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Belgique</li><li>Russie</li><li>Suisse</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>District fédéral central</li><li>New Jersey</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Bruxelles</li><li>Mannheim</li><li>Moscou</li></settlement><orgName><li>Université libre de Bruxelles</li></orgName></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Diel, I J" sort="Diel, I J" uniqKey="Diel I" first="I. J." last="Diel">I. J. Diel</name></region><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><name sortKey="Kreuser, E D" sort="Kreuser, E D" uniqKey="Kreuser E" first="E. D." last="Kreuser">E. D. Kreuser</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Body, J J" sort="Body, J J" uniqKey="Body J" first="J.-J." last="Body">J.-J. Body</name></region></country><country name="Russie"><region name="District fédéral central"><name sortKey="Lichinitser, M R" sort="Lichinitser, M R" uniqKey="Lichinitser M" first="M. R." last="Lichinitser">M. R. Lichinitser</name></region><name sortKey="Gorbunova, V A" sort="Gorbunova, V A" uniqKey="Gorbunova V" first="V. A." last="Gorbunova">V. A. Gorbunova</name></country><country name="Suisse"><noRegion><name sortKey="Budde, M" sort="Budde, M" uniqKey="Budde M" first="M." last="Budde">M. Budde</name></noRegion></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Bergstrom, B" sort="Bergstrom, B" uniqKey="Bergstrom B" first="B." last="Bergström">B. Bergström</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001990 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001990 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:04-0480323
|texte= Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
}}
| This area was generated with Dilib version V0.6.31. |  |